$ARMP
Armata Pharmaceuticals, Inc.

2024 Q4 Form 10-Q Financial Statement

#000155837024015530 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $9.485M
YoY Change 18.89%
% of Gross Profit
Depreciation & Amortization $300.0K
YoY Change 50.0%
% of Gross Profit
Operating Expenses $12.73M
YoY Change 10.1%
Operating Profit -$9.756M
YoY Change -5.61%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $4.275M
YoY Change -120.53%
Pretax Income
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings -$5.481M
YoY Change -82.41%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15
Diluted Earnings Per Share -$0.15
COMMON SHARES
Basic Shares Outstanding 36.18M 36.18M
Diluted Shares Outstanding 36.18M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $17.10M
Short-Term Investments
Other Short-Term Assets $2.219M
YoY Change -73.88%
Inventory
Prepaid Expenses
Receivables
Other Receivables $2.219M
Total Short-Term Assets $22.39M
YoY Change -38.8%
LONG-TERM ASSETS
Property, Plant & Equipment $13.62M
YoY Change 47.2%
Goodwill $3.490M
YoY Change 0.0%
Intangibles $10.26M
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $755.0K
YoY Change -69.43%
Total Long-Term Assets $75.85M
YoY Change -0.43%
TOTAL ASSETS
Total Short-Term Assets $22.39M
Total Long-Term Assets $75.85M
Total Assets $98.24M
YoY Change -12.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.815M
YoY Change -51.88%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $118.2M
YoY Change 440.14%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $118.2M
Total Long-Term Liabilities
Total Liabilities $149.2M
YoY Change 19.23%
SHAREHOLDERS EQUITY
Retained Earnings -$330.3M
YoY Change 14.29%
Common Stock $362.0K
YoY Change 0.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$50.97M
YoY Change
Total Liabilities & Shareholders Equity $98.24M
YoY Change -12.88%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$5.481M
YoY Change -82.41%
Depreciation, Depletion And Amortization $300.0K
YoY Change 50.0%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0000921114
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36122932
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36183067
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37544
dei Entity Registrant Name
EntityRegistrantName
ARMATA PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1549568
dei Entity Address Address Line1
EntityAddressAddressLine1
5005 McConnell Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90066
dei City Area Code
CityAreaCode
310
dei Local Phone Number
LocalPhoneNumber
665-2928
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ARMP
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36183067
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17141000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13523000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3029000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2265000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2219000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3363000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
22389000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19151000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5480000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5720000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13616000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12559000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
42251000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44717000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10256000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10256000
CY2024Q3 us-gaap Goodwill
Goodwill
3490000
CY2023Q4 us-gaap Goodwill
Goodwill
3490000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
755000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2470000
CY2024Q3 us-gaap Assets
Assets
98237000
CY2023Q4 us-gaap Assets
Assets
98363000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3714000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5689000
CY2024Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1580000
CY2023Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
768000
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
41357000
CY2024Q3 armp Long Term Debt Current Maturities Other Than Convertible Debt Current
LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent
66046000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4994000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9481000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
513000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
523000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
118204000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16461000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27929000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28583000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
58633000
CY2023Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
23674000
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3077000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3077000
CY2024Q3 us-gaap Liabilities
Liabilities
149210000
CY2023Q4 us-gaap Liabilities
Liabilities
130428000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
217000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36183067
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36122932
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36122932
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
362000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
361000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
279000000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
276393000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-330335000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308819000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-50973000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-32065000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98237000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98363000
CY2024Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
2973000
CY2023Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1225000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
3939000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
3001000
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9485000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7978000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
25975000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
25842000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3244000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3583000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9861000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8470000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
12729000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
11561000
us-gaap Operating Expenses
OperatingExpenses
35836000
us-gaap Operating Expenses
OperatingExpenses
34312000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9756000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10336000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31897000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31311000
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
294000
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
47000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
567000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
111000
CY2024Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2923000
CY2023Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1176000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7462000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1176000
CY2024Q3 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
6904000
CY2023Q3 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-15833000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
17276000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-12959000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3863000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3863000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4275000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20825000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10381000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17887000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5481000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-31161000
us-gaap Net Income Loss
NetIncomeLoss
-21516000
us-gaap Net Income Loss
NetIncomeLoss
-49198000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.36
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36180124
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36180124
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36086990
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36086990
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36153388
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36153388
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36067025
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36067025
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
19143000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-373000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-31161000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-12386000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-46101000
CY2024Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-61000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
670000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5481000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-50973000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
36080000
armp Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings
RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
18000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
745000
us-gaap Net Income Loss
NetIncomeLoss
-49198000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-12386000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-32065000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
130000
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-61000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2539000
us-gaap Net Income Loss
NetIncomeLoss
-21516000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-50973000
us-gaap Profit Loss
ProfitLoss
-21516000
us-gaap Profit Loss
ProfitLoss
-49198000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
945000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
679000
us-gaap Share Based Compensation
ShareBasedCompensation
2539000
us-gaap Share Based Compensation
ShareBasedCompensation
745000
armp Increase Decrease Fair Value Of Liabilities
IncreaseDecreaseFairValueOfLiabilities
-17276000
armp Increase Decrease Fair Value Of Liabilities
IncreaseDecreaseFairValueOfLiabilities
12959000
us-gaap Other Noncash Expense
OtherNoncashExpense
7483000
us-gaap Other Noncash Expense
OtherNoncashExpense
1176000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3863000
armp Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1489000
armp Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-662000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2095000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
72000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2031000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-321000
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
812000
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-87000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4164000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9723000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29624000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39317000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1956000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5744000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1956000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5744000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
29101000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
34889000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
24925000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
61000
armp Proceeds From Exercise Of Warrants And Stock Options
ProceedsFromExerciseOfWarrantsAndStockOptions
130000
armp Proceeds From Exercise Of Warrants And Stock Options
ProceedsFromExerciseOfWarrantsAndStockOptions
5000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34958000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54031000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3378000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8970000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19243000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20812000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22621000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29782000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
977000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2513000
us-gaap Contribution Of Property
ContributionOfProperty
263000
us-gaap Contribution Of Property
ContributionOfProperty
1047000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17141000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23958000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5480000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5824000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22621000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29782000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-330300000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to convertible debt, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risks and Certain Other Risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and restricted cash. As of September 30, 2024, cash equivalents and restricted cash was invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions in accordance with the Company’s investment policy, to a concentration limit per issuer or sector. These are investment assets and are classified as cash equivalents in the condensed consolidated balance sheets as their original maturities are less than three months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other receivables represent amounts due from the Medical Technology Enterprise Consortium (“MTEC”) (Note 13) and reimbursement for tenant improvements (Note 12).</p>
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10355000
CY2024Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
41357000
CY2023Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
58633000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5481000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-31161000
us-gaap Net Income Loss
NetIncomeLoss
-21516000
us-gaap Net Income Loss
NetIncomeLoss
-49198000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36180124
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36180124
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36086990
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36086990
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36153388
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36153388
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36067025
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36067025
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.36
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
46026192
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
44024924
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26382000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24380000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12766000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11821000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13616000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12559000
CY2024Q3 us-gaap Depreciation
Depreciation
300000
CY2023Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
900000
us-gaap Depreciation
Depreciation
700000
CY2024Q3 armp Construction In Progress And Fixed Assets Not In Use Included In Laboratory And Manufacturing Equipment
ConstructionInProgressAndFixedAssetsNotInUseIncludedInLaboratoryAndManufacturingEquipment
9600000
CY2023Q4 armp Construction In Progress And Fixed Assets Not In Use Included In Laboratory And Manufacturing Equipment
ConstructionInProgressAndFixedAssetsNotInUseIncludedInLaboratoryAndManufacturingEquipment
8100000
CY2024Q3 armp Tenant Improvement Receivable Current
TenantImprovementReceivableCurrent
597000
CY2023Q4 armp Tenant Improvement Receivable Current
TenantImprovementReceivableCurrent
1835000
CY2024Q3 armp Grant And Award Receivable Current
GrantAndAwardReceivableCurrent
1622000
CY2023Q4 armp Grant And Award Receivable Current
GrantAndAwardReceivableCurrent
1528000
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2219000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3363000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1815000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1585000
CY2024Q3 armp Accrued Liabilities Clinical Trial
AccruedLiabilitiesClinicalTrial
1567000
CY2023Q4 armp Accrued Liabilities Clinical Trial
AccruedLiabilitiesClinicalTrial
3021000
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
332000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
1083000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3714000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5689000
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19365847
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3934731
CY2024Q3 us-gaap Employee Stock Ownership Plan Esop Number Of Committed To Be Released Shares
EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
11890
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19365847
CY2024Q3 armp Shares Issuable Upon Conversion Of Convertible Debt
SharesIssuableUponConversionOfConvertibleDebt
22495614
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
49257240
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3219158
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3165216
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.04
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
429000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1784054
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.38
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
37282
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
24000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
977257
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.10
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3934731
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3934731
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
15000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2094287
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.07
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
670000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-373000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2539000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
745000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 armp Annual Increase In Rent Percentage
AnnualIncreaseInRentPercentage
0.03
CY2021Q4 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P16Y
CY2021Q4 armp Base Annual Rent To Be Paid Year Three
BaseAnnualRentToBePaidYearThree
300000
CY2021Q4 armp Allowance For Tenant Improvements Receivable
AllowanceForTenantImprovementsReceivable
7200000
CY2021Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
5000000.0
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
836000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5139000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5293000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5452000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5616000
CY2024Q3 armp Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
43779000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
66115000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
33192000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
32923000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4994000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27929000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
2000000.0
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
2100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
6300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
5700000
CY2024Q3 us-gaap Variable Lease Payment
VariableLeasePayment
400000
CY2023Q3 us-gaap Variable Lease Payment
VariableLeasePayment
500000
us-gaap Variable Lease Payment
VariableLeasePayment
1400000
us-gaap Variable Lease Payment
VariableLeasePayment
900000
us-gaap Operating Lease Payments
OperatingLeasePayments
2006000
us-gaap Operating Lease Payments
OperatingLeasePayments
3223000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y11M19D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y9M14D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.139
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.139
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-015530-index-headers.html Edgar Link pending
0001558370-24-015530-index.html Edgar Link pending
0001558370-24-015530.txt Edgar Link pending
0001558370-24-015530-xbrl.zip Edgar Link pending
armp-20240930.xsd Edgar Link pending
armp-20240930x10q.htm Edgar Link pending
armp-20240930x10q001.jpg Edgar Link pending
armp-20240930xex31d1.htm Edgar Link pending
armp-20240930xex31d2.htm Edgar Link pending
armp-20240930xex32d1.htm Edgar Link pending
armp-20240930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
armp-20240930_def.xml Edgar Link unprocessable
armp-20240930_lab.xml Edgar Link unprocessable
armp-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
armp-20240930x10q_htm.xml Edgar Link completed
armp-20240930_cal.xml Edgar Link unprocessable